Figure 1.
Figure 1. Synergy between pPIMi and idelalisib in primary CLL patient samples supports dual inhibition of PIM and PI3-kinase by IBL-202.

Synergy between pPIMi and idelalisib in primary CLL patient samples supports dual inhibition of PIM and PI3-kinase by IBL-202.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal